参考文献/References:
[1] Ramphal R, Pappo A, Zielenska M, et al. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family [J]. Am J Clin Pathol, 2006, 126(3): 349-364.
[2] Bambury RM, Battley JE, Mccarthy A, et al. Translocation renal cell carcinomas: an evolving entity and a member of the microphthalmia transcription factor-associated family of tumors[J].Clin Genitourin Cancer, 2013, 11(3): 357-361.
[3] Argani P, Ladanyi M. Translocation carcinomas of the kidney [J]. Clin Lab Med, 2005, 25(2): 363-378.
[4] Zhong M, De Angelo P, Osborne L, et al. Translocation renal cell carcinomas in adults: a single-institution experience[J]. Am J Surg Pathol, 2012, 36(5): 654-662.
[5] Armah HB, Parwani AV, Surti U, et al. Xp11.2 translocation renal cell carcinoma occurring during pregnancy with a novel translocation involving chromosome 19: a case report with review of the literature[J]. Diagn Pathol, 2009, 4: 15.
[6] Argani P, Ladanyi M. The evolving story of renal translocation carcinomas[J]. Am J Clin Pathol, 2006, 126(3): 332-334.
[7] Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma [J]. Cancer,2010, 116(22):5219-5225.
[8] Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry [J]. Clin Cancer Res, 2009, 15 (4):1170-1176.
[9] Sukov WR, Hodge JC, Lohse CM, et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients [J]. Am J Surg Pathol, 2012, 36(5): 663-670.
[10] Chen CJ, Hsu HT, Lin MT, et al. Renal cell carcinoma with t(X;17)(p11.2;q25) in a 5-year-old Taiwanese boy: a case report and review of the literature[J]. Pathol Oncol Res, 2012, 18(1): 111-116.
[11] Ross H, Argani P. Xp11 translocation renal cell carcinoma [J].Pathology, 2010, 42(4): 369-373.
[12] Rais-Bahrami S, Drabick JJ, De Marzo AM, et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy [J]. Urology, 2007, 70(1): 173-178.
[13] Suzigan S, Drut R, Faria P, et al. Xp11 translocation carcinoma of the kidney presenting with multilocular cystic renal cell carcinoma-like features [J]. Int J Surg Pathol, 2007, 15 (2):199-203.
[14] Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum[J]. Am J Surg Pathol, 2007, 31(8): 1149-1160.
[15] Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions:a sensitive and specific immunohistochemical assay[J]. Am J Surg Pathol, 2003, 27(6): 750-761.
[16] Nelius T, Al-Khalil I, Vordermark J, et al. TFE3 translocation-associated renal cell carcinoma presenting as avascular necrosis of the femur in a 19-year-old patient: case report and review of the literature [J]. Case Rep Med, 2011, 2011:432917.
[17] Zhu QQ, Wang ZQ, Zhu WR, et al. The multislice CT findings of renal carcinoma associated with XP11.2 translocation/TFE gene fusion and collecting duct carcinoma[J]. Acta Radiol, 2013, 54(3):355-362.
[18] 薛彦诗, 甘卫东, 刘铁石, 等. Xp11.2 易位/TFE3 基因融合相关性肾癌的临床与病理分析[J]. 江苏医药, 2012, 33(5): 537-540.
[19] 徐晓晨, 甘卫东, 李笑弓, 等. Xp11.2 易位/TFE3 基因融合相关性肾癌与肾透明细胞癌的螺旋CT 诊断鉴别[J]. 现代泌尿外科杂志, 2012, 17(2): 122-124.
[20] Kato H, Kanematsu M, Yokoi S, et al. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion:radiological findings mimicking papillary subtype. J Magn Reson Imaging, 2011, 33(1): 217-220.
[21] Klatte T, Streubel B,Wrba F, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation:incidence, characteristics, and prognosis[J]. Am J Clin Pathol,2012, 137(5): 761-768.
[22] Gaillot-Durand L, Chevallier M, Colombel M, et al. Diagnosis of Xp11 translocation renal cell carcinomas in adult patients under 50 years: interest and pitfalls of automated immunohistochemical detection of TFE3 protein[J]. Pathol Res Pract, 2013, 209(2):83-89.
[23] Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas [J]. Mod Pathol, 2009, 22(8): 1016-1022.
[24] Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service [J].Am J Surg Pathol, 2013, 37(8): 1150-1163.
[25] Rao Q, Williamson S R, Zhang S, et al. TFE3 Break-apart FISH Has a Higher Sensitivity for Xp11.2 Translocation-associated Renal Cell Carcinoma Compared With TFE3 or Cathepsin K Immunohistochemical Staining Alone: Expanding the Morphologic Spectrum[ J ] . Am J Surg Pathol , 2013, 37 (6) :804-815.
[26] Hou MM, Hsieh JJ, Chang NJ, et al. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma[J].Clin Drug Investig, 2010, 30(11): 799-804.
[27] Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network[J].Ann Oncol, 2010, 21(9): 1834-1838.
[28] Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition[J]. Cancer Res, 2007, 67(3): 919-929.
[29] Jayasinghe C, Siegler N, Leuschner I, et al. Renal cell carcinoma with Xp11.2 translocation in a 7-year-old boy [J]. Klin Padiatr,2010, 222(3): 187-189.
[30] Fall B, Sarr A, Sow Y, et al. Renal cell carcinoma with MiTF/TFE3 translocation in children: report of a case at the stage of lymph node involvement[J]. Afr J Paediatr Surg, 2011, 8(3):317-319.
[31] Meyer PN, Clark JI, Flanigan RC, et al. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults[J]. Am J Clin Pathol, 2007, 128(1): 70-79.
[32] Arnoux V, Long JA, Fiard G, et al. Xp11.2 translocation renal carcinoma in adults over 50 years of age: about four cases [J].Prog Urol, 2012, 22(15): 932-937.
[33] Mir M C, Trilla E, de Torres I M, et al. Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome[J]. BJU Int, 2011,108(2 Pt 2): E71-E76.
[34] Malouf GG, Camparo P, Molinie V, et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors [J]. J Urol,2011, 185(1): 24-29.
相似文献/References:
[1]湛海伦,高新,蔡育彬,等.腹腔镜肾癌根治术联合DC-CIK细胞免疫治疗的临床疗效[J].中华腔镜泌尿外科杂志(电子版),2007,(02):112.
ZHAN Hai-lun,GAO Xin,CAI Yu-bing,et al.Clinical efficacy of laparoscopic radical nephrectomy combined DC-CIK cells immunotherapy in renal cell carcinoma[J].,2007,(05):112.
[2]张宇,刘东,胡岚亭,等.后腹腔镜与开放肾部分切除术治疗局限性肾癌的疗效比较[J].中华腔镜泌尿外科杂志(电子版),2013,(01):9.
ZHANG Yu,LIU Dong,HU Lan-Ting,et al.Comparison of retroperitoneal laparoscopic and open partial nephrectomy in local renal cell carcinoma[J].,2013,(05):9.
[3]范大为刘凯袁成刚杜晓媛.Beclin-1在肾癌组织中的表达及其临床意义[J].中华腔镜泌尿外科杂志(电子版),2015,(02):96.[doi:10.3877/cma.j.issn.1674-3253.2015.02.004
]
Fan Dawei,Liu Kai Yuan Chenggang,et al.Expression level and clinical significance of Beclin-1 in renal cell carcinoma[J].,2015,(05):96.[doi:10.3877/cma.j.issn.1674-3253.2015.02.004
]
[4]加素尔 ?吐尔,徐铭泽,唐钵,等.广东省医学会泌尿外科疑难病例多学科会诊（第14期）——左肾原发罕见恶性肿瘤并全身多处转移[J].中华腔镜泌尿外科杂志(电子版),2024,18(01):110.[doi:10.3877/cma.j.issn.1674-3253.2024.01.021]
[J].,2024,18(05):110.[doi:10.3877/cma.j.issn.1674-3253.2024.01.021]
[5]邓新军,李正明,李文彬.广东省医学会泌尿外科疑难病例多学科会诊（第14期）——左肾原发恶性肿瘤并发于肺癌并脑转移[J].中华腔镜泌尿外科杂志(电子版),2024,18(01):114.[doi:10.3877/cma.j.issn.1674-3253.2024.01.022]
[J].,2024,18(05):114.[doi:10.3877/cma.j.issn.1674-3253.2024.01.022]